Karo Pharma Ab Stock Fundamentals
| KARBFDelisted Stock | USD 5.25 0.00 0.00% |
Karo Pharma AB fundamentals help investors to digest information that contributes to Karo Pharma's financial success or failures. It also enables traders to predict the movement of Karo Pink Sheet. The fundamental analysis module provides a way to measure Karo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Karo Pharma pink sheet.
Karo |
Karo Pharma AB Company Return On Asset Analysis
Karo Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Karo Pharma Return On Asset | 0.0017 |
Most of Karo Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Karo Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Karo Pharma AB has a Return On Asset of 0.0017. This is 100.02% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is 101.21% lower than that of the firm.
Karo Pharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Karo Pharma's current stock value. Our valuation model uses many indicators to compare Karo Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Karo Pharma competition to find correlations between indicators driving Karo Pharma's intrinsic value. More Info.Karo Pharma AB is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Karo Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Karo Pharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Karo Pharma's earnings, one of the primary drivers of an investment's value.Karo Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karo Pharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Karo Pharma could also be used in its relative valuation, which is a method of valuing Karo Pharma by comparing valuation metrics of similar companies.Karo Pharma is currently under evaluation in return on asset category among related companies.
Karo Fundamentals
| Return On Equity | -0.0269 | |||
| Return On Asset | 0.0017 | |||
| Profit Margin | (0.05) % | |||
| Current Valuation | 2.34 B | |||
| Shares Outstanding | 273.26 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 88.29 % | |||
| Price To Earning | 262.50 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 4.49 X | |||
| Revenue | 2.96 B | |||
| Gross Profit | 1.71 B | |||
| EBITDA | 761.36 M | |||
| Net Income | (17.45 M) | |||
| Cash And Equivalents | 33.24 M | |||
| Cash Per Share | 0.30 X | |||
| Total Debt | 5.58 B | |||
| Debt To Equity | 1.06 % | |||
| Current Ratio | 2.71 X | |||
| Book Value Per Share | 2.30 X | |||
| Cash Flow From Operations | 532.6 M | |||
| Earnings Per Share | 0.02 X | |||
| Number Of Employees | 225 | |||
| Beta | 0.1 | |||
| Market Capitalization | 1.52 B | |||
| Total Asset | 12.59 B | |||
| Retained Earnings | (1.13 B) | |||
| Working Capital | 201 M | |||
| Current Asset | 288 M | |||
| Current Liabilities | 87 M | |||
| Net Asset | 12.59 B |
About Karo Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Karo Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karo Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Karo Pharma AB develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. Karo Pharma AB was incorporated in 1987 and is headquartered in Stockholm, Sweden. Karo Pharma is traded on OTC Exchange in the United States.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Karo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Karo Pharma's short interest history, or implied volatility extrapolated from Karo Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Karo Pharma AB information on this page should be used as a complementary analysis to other Karo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Karo Pink Sheet
If you are still planning to invest in Karo Pharma AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karo Pharma's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |